Dynamic ProGRP Changes During Ewing Sarcoma Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this single-center observational study, researchers will collect blood samples at four key time points and compare ProGRP changes with tumor size changes on RECIST imaging. Radiologists will assess imaging independently to see if early ProGRP shifts can predict radiographic response. The goal is to understand whether ProGRP could serve as a biomarker for treatment response, without affecting clinical decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 10 to 60 years.
* Histologically confirmed Ewing sarcoma.
* Newly diagnosed disease and scheduled to initiate first-line systemic therapy at Peking University People's Hospital.
* No prior systemic chemotherapy for Ewing sarcoma and no prior radiotherapy to the primary tumor.
* At least one evaluable lesion on baseline imaging; at least one measurable lesion according to RECIST version 1.1 is required for the primary outcome analysis.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
* Estimated life expectancy greater than 3 months.
* Written informed consent provided by the participant or the participant's legally authorized representative.

Exclusion Criteria:

* History of another malignant tumor within the previous 3 years, except for an adequately treated malignancy with a negligible risk of recurrence, as determined by the investigator.
* New York Heart Association (NYHA) class III or IV heart failure.
* Uncontrolled concomitant illness, including uncontrolled diabetes mellitus or an active infection.
* Severe infection requiring intravenous antimicrobial treatment within 4 weeks before enrollment.
* Clinically significant bleeding or a clear bleeding tendency within 3 months before enrollment.
* Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m².
* Pregnancy or breastfeeding.
* Any condition that, in the investigator's judgment, may compromise participant safety, interfere with study assessments, or prevent compliance with the protocol.

Where it's running

• Peking University People's Hospital, Beijing, Beijing 100044
  Beijing, China Recruiting

Study contacts

• Study coordinator: Lu Xie, M.D.
• Email: xie.lu@hotmail.com
• Phone: +8613401044719

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

  This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07514819

• Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

  This trial tests whether adding eflornithine (DFMO) as extra or maintenance therapy can improve survival for young people with Ewing sarcoma or osteosarcoma.

  Recruiting at 3 sites Phase 2 Milton S. Hershey Medical Center · Tampa, Florida and 2 other locations · NCT07321912

• Xaluritamig for relapsed or refractory Ewing sarcoma in adults, adolescents, and children

  This trial will test xaluritamig in adults, adolescents, and children with relapsed or refractory Ewing sarcoma to find a recommended dose for expansion and check safety and tolerability.

  Recruiting at 13 sites Phase 1 Amgen · Los Angeles, California and 12 other locations · NCT07297979

• Hypofractionated radiation plus B7-H3 CAR T cells for children and young adults with relapsed sarcoma

  This will test whether short-course radiation given before B7-H3 CAR T-cell therapy is safe for children and young adults (≤21) with relapsed or refractory B7-H3–positive sarcomas.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07222735

• ST-01156, a drug that degrades RBM39, for advanced solid cancers

  This trial will test whether ST-01156 is safe and shows early anti-cancer activity in adults (and some teens with Ewing sarcoma) who have advanced or metastatic solid tumors like liver, biliary tract, or Ewing sarcoma.

  Recruiting at 6 sites Phase 1 SEED Therapeutics, Inc. · Duarte, California and 5 other locations · NCT07197554

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.